CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Liminatus Pharma selects Synex to advance CAR-T trial

Phase 1IBC101Neutral
AI Analysis

Summary

Liminatus Pharma has engaged Korean CRO Synex Consulting to provide clinical research services for the Phase I/IIa study of CAR-T candidate IBC101.

Clinical Trial Data

Phase

Phase I/IIa

Importance:3/10
Sentiment:
0.00
CAR-Tclinical trialCRO engagementPhase 1
Related Companies

Read the original article

Published by Clinical Trials Arena on August 25, 2026 9:45 AM

Read Original